阿尔茨海默病血液生物标志物:对人口水平使用的考虑
Michelle M Mielke1, Nicole R Fowler2,3,4
1Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, NC, USA. mmielke@wakehealth.edu.
Nature reviews. Neurology
|June 11, 2024
概括
基于血液的生物标志物 (BBM) 为诊断阿尔茨海默病 (AD) 提供了一种更容易获得的方法. 本综述探讨了在人口层面有效实施这些生物标志物的关键考虑因素.
科学领域:
- 神经学 神经学
- 生物标志物开发 生物标志物开发
- 公共卫生 公共卫生
背景情况:
- 最近的进展包括阿尔茨海默病 (AD) 的第一个疾病修饰疗法和基于血液的生物标志物 (BBM) 的开发.
- BBM为AD诊断提供了一种更容易获得,更少入侵和更具成本效益的替代方案,而不是收集脑脊髓液或神经成像.
- 对BBM的广泛采用需要解决其在人口层面的实施和解释方面的挑战.
研究的目的:
- 审查目前的AD生物标志物,包括BBMs的风景.
- 在初级保健机构中确定对AD BBMs广泛实施和解释至关重要的因素.
- 讨论将BBM纳入常规临床实践的更广泛影响.
主要方法:
- 关于当前使用AD生物标志物的文献综述.
- 在初级保健中对患者特征的分析与研究队列的分析.
- 检查影响BBM测试解释的因素.
主要成果:
- 初级保健患者群体与AD BBM研究中的患者群体有所不同.
- 伴随性疾病,性别和种族/种族可以影响BBM测试的解释.
- 伦理考虑,患者/提供者偏好和结果管理至关重要.
结论:
- 成功地在人口层面实施AD BBMs需要仔细考虑各种患者因素和后勤挑战.
- 解决不确定的结果和不完美的准确性等问题对于可靠的临床使用至关重要.
- 需要一个全面的方法来有效地将BBMs整合到AD诊断和管理中.
更多相关视频
07:20Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
Published on: January 28, 2014
36.4K
11:03Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
Published on: February 10, 2020
7.3K
相关概念视频
01:26Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462
01:22Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179